fda warning letter hims compounded semaglutide september 2025 issued 25 letters to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Takes Aim at Hims

Understanding when compounded semaglutide expires prevents you from using degraded product

S2CID 220329737

Clinical evidence from extension trials suggests this reduces monthly costs by 2540% while maintaining 6075% of the weight loss achieved at higher doses, though individual response varies significantly

Dosing errors waste money and reduce results

Genetic variants associated with GLP-1 receptor expression and their effects on psychiatric and neurodevelopmental conditions may vary across populations due to differences in allele frequencies, linkage disequilibrium patterns, and environmental exposures

Preclinical research has demonstrated that GLP-1 receptor activation may confer neuroprotective effects through multiple mechanisms